The use of a cyclooxygenase-2 inhibitor (Nepafenac) in an ocular and metastatic animal model of uveal melanoma

Carcinogenesis

Volumn 28, Issue 9, 2007, Pages 2053-2058

  Marshall, Jean Claude A ^a   Fernandes, Bruno F ^a   Di cesare, Sebastian ^a   Maloney, Shawn C ^a   Logan, Patrick T ^a   Antecka, Emilia ^a   Burnier Jr , Miguel N ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NEPAFENAC;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD SAMPLING; CANCER INHIBITION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; HISTOPATHOLOGY; INOCULATION; MALE; METASTASIS; NONHUMAN; OPHTHALMOSCOPY; PRIORITY JOURNAL; RABBIT; TREATMENT DURATION; UVEA MELANOMA;

ANIMALS; BENZENEACETAMIDES; CYCLOOXYGENASE 2 INHIBITORS; MELANOMA; MODELS, ANIMAL; NEOPLASM METASTASIS; PHENYLACETATES; RABBITS; UVEAL NEOPLASMS;

EID: 34848922151     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm091     Document Type: Article

References (39)

1. Chang,M. et al. (1984) The persisting pseudomelanoma problem. Arch. Ophthalmol., 102, 726-727.
2. COMS (1990) Accuracy of diagnosis of choroidal melanomas in the Collaborative Ocular Melanoma Study. COMS report no. 1. Arc. Ophthalmol., 108, 1268-1273.
3. Singh,A.D. et al. (2003) Survival rates with uveal melanoma in the United States: 1973-1997. Ophthalmology, 110, 962-965.
4. Jensen,O.A. (1982) Malignant melanomas of the human uvea: 25-year follow-up of cases in Denmark, 1943-1952. Acta. Ophthalmol. (Copenh.) 60, 161-182.
5. Raivio,I. (1977) Uveal melanoma in Finland. An epidemiological, clinical, histological and prognostic study. Acta. Ophthalmol. Suppl. 133, 1-64.
6. Kath,R. et al. (1993) Prognosis and treatment of disseminated uveal melanoma. Cancer, 72, 2219-2223.
7. Lorigan,J.G. et al. (1991) The prevalence and location of metastases from ocular melanoma: Imaging study in 110 patients. AJR Am. J. Roentgenol., 157, 1279-1281.
8. Rajpal,S. et al. (1983) Survival in metastatic ocular melanoma. Cancer, 52, 334-336.
9. Rietschel,P. et al. (2005) Variates of survival in metastatic uveal melanoma. J. Clin. Oncol., 23, 8076-8080.
10. Singh,A.D. et al. (2005) Metastatic uveal melanoma. Ophthalmol. Clin. North Am., 18, 143-150ix.
11. Figueiredo,A. et al. (2003) Cyclooxygenase-2 expression in uveal melanoma: Novel classification of mixed-cell-type tumours. Can. J. Ophthalmol., 38, 352-356.
12. Tang,T.C. et al. (2005) Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. World J. Gastroenterol., 11, 1896-1902.
13. Dai,Y. et al. (2005) The expression of cyclooxygenase-2, VEGF and PGs in CIN and cervical carcinoma. Gynecol. Oncol., 97, 96-103.
14. Soumaoro,L.T. et al. (2004) Cyclooxygenase-2 expression: A significant prognostic indicator for patients with colorectal cancer. Clin. Cancer Res., 10, 8465-8471.
15. Patel,M.I. et al. (2005) Celecoxib inhibits prostate cancer growth: Evidence of a cyclooxygenase-2-independent mechanism. Clin. Cancer Res., 11, 1999-2007.
16. Williams,C.S. et al. (2001) A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts. Neoplasia, 3, 428-436.
17. Kojima,M. et al. (2001) Association of enhanced cyclooxygenase-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann. Surg. Oncol., 8, 458-465.
18. Yao,M. et al. (2005) Effects of nonselective cyclooxygenase inhibition with low-dose ibuprofen on tumor growth, angiogenesis, metastasis, and survival in a mouse model of colorectal cancer. Clin. Cancer Res., 11, 1618-1628.
19. Evans,D.M. et al. (2004) Control of pulmonary metastases of rat mammary cancer by inhibition of uPA and COX-2, singly and in combination. Clin. Exp. Metastasis, 21, 339-346.
20. Steinbach,G. et al. (2000) The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342, 1946-1952.
21. Arun,B. et al. (2004) The role of COX-2 inhibition in breast cancer treatment and prevention. Semin. Oncol., 31, 22-29.
22. Kapin,M.A. et al. (2003) Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation, 27 281-291.
23. Takahashi,K. et al. (2003) Topical nepafenac inhibits ocular neovascularization. Invest. Ophthalmol. Vis. Sci., 44, 409-415.
24. Gamache,D.A. et al. (2000) Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation, 24, 357-370.
25. Graham,D.J. et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancer, 365, 475-481.
26. Blanco,P.L. et al. (2005) Characterization of ocular and metastatic uveal melanoma in an animal model. Invest. Ophthalmol. Vis. Sci., 46, 4376-4382.
27. Yang,H. et al. (2006) Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. Curr. Eye Res., 31, 557-562.
28. Tolleson,W.H. et al. (2005) Spontaneous uveal amelanotic melanoma in transgenic Tyr-RAS+ Ink4a/Arf-/- mice. Arch. Ophthalmol., 123, 1088-1094.
29. Notting,I.C. et al. (2005) Whole-body bioluminescent imaging of human uveal melanoma in a new mouse model of local tumor growth and metastasis. Invest. Ophthalmol. Vis. Sci., 46, 1581-1587.
30. Blanco,G. et al. (2000) Uveal melanoma model with metastasis in rabbits: Effects of different doses of cyclosporine A. Curr. Eye Res. 21, 740-747.
31. De Waard-Siebinga,I. et al. (1995) Establishment and characterization of an uveal-melanoma cell line. Int. J. Cancer, 62, 155-161.
32. Marshall,J.C. et al. (2004) Cell proliferation profile of five human uveal melanoma cell lines of different metastatic potential. Pathobiology, 71, 241-245.
33. Lopez-Velasco,R. et al. (2005) Efficacy of five human melanocytic cell lines in experimental rabbit choroidal melanoma. Melanoma Res. 15, 29-37.
34. McLean,I.W. et al. (2004) Pathological and prognostic features of uveal melanomas. Can. J. Ophthalmol., 39, 343-350.
35. Marshall,J.C. et al. (2007) The effects of a cyclooxygenase-2 (COX-2) expression and inhibition on human uveal melanoma cell proliferation and macrophage nitric oxide production. Ophthalmic Res. n press.
36. Basu,G.D. et al. (2006) A novel role for cyclooxygenase-2 in regulating vascular channel formation by human breast cancer cells. Breast Cancer Res., 8, R69-R80.
37. Larkins,T.L. et al. (2006) Inhibition of cyclooxygenase-2 decreases breast cancer cell motility, invasion and matrix metalloproteinase, expression. BMC Cancer, 6, 181.
38. Lin,H.P. et al. (2004) Growth inhibitory effects of celecoxib in human umbilical vein endothelial cells are mediated through G1 arrest via multiple signaling mechanisms. Mol. Cancer Ther., 3, 1671-1690.
39. Callejo,S.A. et al. (2006) Identification of circulating malignant cells and its correlation with prognostic factors and treatment in uveal melanoma. A prospective longitudinal study. Eye.